CClinicalTrials.gg
WithdrawnNCT03255473Updated Oct 15, 2024

High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

A Phase 2 interventional study of Dexamethasone and Prednisone in Sudden Sensorineural Hearing Loss (SSNHL), sponsored by University of Colorado, Denver. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

Why this study was withdrawn
On hold due to COVID-19 outbreak
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Compare hearing outcomes between treatment with dexamethasone versus prednisone in participants who have been diagnosed with unilateral SSNHL (sudden sensorineural hearing loss).

Read the detailed description

Sudden sensorineural hearing loss (SSNHL) affects approximately 5 to 20 per 100,000 persons with spontaneous recovery seen in 32% to 65%. Many different treatments have been investigated in attempt to improve hearing outcomes, with oral corticosteroids having some success. Steroid regimens are highly variable, however, retrospective data has suggested greater improvement in hearing outcomes with the use of high dose oral steroids (dexamethasone) in the setting of unilateral sudden sensorineural hearing loss compared to traditional medical therapy with lower dose oral prednisone. The investigators hypothesize that patients with unilateral SSNHL who are randomized to treatment with high doses of oral dexamethasone will show better hearing outcomes than patients who are randomized to the more common standard clinical practice treatment with lower doses of oral prednisone.

02

Conditions studied

  • Sudden Sensorineural Hearing Loss (SSNHL)
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 to 80 years old
  • Present to the Otology or Otolaryngology Clinic at the University of Colorado Hospital with unilateral sudden sensorineural hearing loss (SSNHL)
  • Seen within six weeks of initial hearing loss
  • Unilateral hearing loss at screening as defined by:

    • Loss of 30 decibels (dB) HL or greater over 3 continuous frequencies with participants reporting that this hearing loss occurred within 3 days
  • Present with primary complaint of sensorineural hearing loss
  • Normal tympanometry (Type A)
  • Normal tympanic membrane

Exclusion criteria

Exclusion Criteria:

  • Participants for whom high dose corticosteroids are a contraindicated due to:

    • Pregnancy
    • Known allergies to corticosteroids
    • Other concurrent medical conditions and or medications where high dose oral corticosteroids are not safe to use
  • Participants who have Type 1 or Type 2 diabetes
  • Participants who have previously received a course of oral steroids for this indication
  • Participants who have bilateral SSNHL
  • Participants with conductive hearing loss, mixed hearing loss (sensorineural and conductive), or any type of hearing loss that is not SSNHL (i.e. caused by acoustic or physical trauma to the ear)
  • Participants with the following conditions/situations will be excluded because the possibility that these could cause SSNHL:

    • History of previous/recurrent unilateral SSNHL
    • History of fluctuating hearing in either ear
    • History of Meniere's syndrome
    • History of chronic granulomatous or suppurative otitis media or cholesteatoma in either ear
    • History of otosclerosis in either ear
  • Participants with the following conditions/situations will be excluded due to risk of misclassification of diagnosis of idiopathic SSNHL or because these participants are at higher risk for potential steroid side effects due to other comorbidities. If the time line is not otherwise stated, then the participant will be excluded if they experienced these criteria at any point in their lifetime:

    • Received oral steroids (for any indication besides SSNHL) for greater than 21 days in the preceding 30 days
    • Systemic fungal infections in the last 6 months
    • History of tuberculosis or history of prophylactic tuberculosis treatment for positive skin test (PPD)
    • History of unstable angina, coronary artery stenting or bypass graft within 3 months
    • History of transient ischemic attacks, cardiac arrhythmia, or stroke in the last 4 weeks
    • Serious psychiatric disease or history of psychiatric reaction to corticosteroids, specifically bipolar, schizophrenia, episodes of mania or delirium
    • Prior treatment with chemotherapy agents, immunosuppressive drugs, cyclosporine, or interferon
    • Pancreatitis in the last year
    • Active peptic ulcer disease or history of gastrointestinal bleeding in the last year
    • History of known HIV, hepatitis C, or hepatitis B infection
    • Chronic renal insufficiency requiring dialysis
    • Active shingles (herpes zoster infection)
    • Advanced/severe osteoporosis or nonsurgical aseptic necrosis of the hip
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Dexamethasone

    All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.

    Drug: Dexamethasone

  • Active comparator
    Prednisone

    All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.

    Drug: Prednisone

Interventions

  • DrugDexamethasone

    All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.

    Also known as: dexamethasone sodium phosphate

  • DrugPrednisone

    All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.

    Also known as: Deltasone

05

What researchers measure

Primary outcomes

  1. Changes in Hearing Threshold (Hearing Improvement)

    Pure tone averages (from pure tone audiometry) will be recorded for participants at each visit, and assessed for changes in pure tone average over time. Based on a change in pure tone average, participants will be categorized into the different groups.

    Time frame: Baseline, 1 week, 1 month, 3 months

Secondary outcomes

  1. Changes in Word Recognition Scores

    Word recognition scores from speech audiometry tests will be summarized, by treatment arm, as a continuous variable using the mean, standard deviation, median, 25th percentile, 75th percentile, minimum and maximum.

    Time frame: 1 week, 1 month, 3 months, and assessed for change from baseline score.

  2. Changes in Pure Tone Averages

    Continuous pure tone averages calculated from pure tone audiometry will be summarized using the mean, standard deviation, median, 25th percentile, 75th percentile, minimum and maximum and will be presented by treatment arm.

    Time frame: 1 week, 1 month, 3 months, and assessed for change from baseline pure tone average..

  3. Clinical Frequency Analysis Based on Hearing Improvement

    The frequency of patients presenting in each clinical category of hearing improvement will be presented by treatment arm. Hypothesis testing will be performed, using a Mantel-Haenszel Chi-Square test, to test for the association between treatment group and the ordered levels of clinical category of hearing improvement.

    Time frame: Baseline, 1 week, 1 month, 3 months

  4. Clinical Percentage Analysis Based on Hearing Improvement

    The percentage of patients presenting in each clinical category of hearing improvement will be presented by treatment arm. Hypothesis testing will be performed, using a Mantel-Haenszel Chi-Square test, to test for the association between treatment group and the ordered levels of clinical category of hearing improvement.

    Time frame: Baseline, 1 week, 1 month, 3 months

06

Study locations

1 site
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03255473
Lead sponsor
University of Colorado, Denver
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Aug 30, 2017
Primary completion
Aug 1, 2022
Completion
Mar 13, 2023
Last update
Oct 15, 2024

Study contacts

Stephen P Cass, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion